
NASDAQ:PEP
This summary was created by AI, based on 7 opinions in the last 12 months.
PepsiCo (PEP) is experiencing challenges due to the rising popularity of GLP-1 weight-loss drugs among health-conscious consumers, especially the younger generation. Despite its long-standing Frito-Lay snack division and a solid dividend yield of nearly 4%, commentators express concerns about shifting consumer preferences impacting sales. The company reports earnings soon, and while some believe it has strong growth potential, others highlight struggles within the snack division. Activist investor Elliott Management's recent stake in PepsiCo suggests some see it as undervalued, viewing the current price as a bargain. However, there are underlying headwinds, including competition from healthier options and an overall cautious economic outlook that raises questions about future growth prospects.
There is a lot of pressure on carbonated beverages. It’s shrinking year-over-year. This has transitioned away better than Coca-Cola (KO-N) has. More than 50% of revenues comes from non-carbonated beverages. They have over 20 brands that generate over $1 billion a year. He would consider this if it were cheaper. Trading at over 20X Price to Earnings.
The PepsiCo (PEP-N) Coca-Cola (KO-N) Rivalry never seems to end. Of the 2, he would prefer PepsiCo, but doesn't own either. It has done a better job of diversifying away from the reliance on carbonated soft drinks. Today, more than 50% of their revenues come from noncarbonated drinks. There is still a lot of uncertainty as to what this kind of business looks like 5 years from now. He would not be a buyer at this time.
Stochchase Research Editor: Michael O'Reilly We are encouraged by the rebound in PEP stock recently. As we head into the next round of the pandemic, with more people at home for the holidays, we should expect sales to continue to recover. Analysts are calling for EPS of $1.47-$1.52, which would put it on track with last year's levels. We would look to buy on an opportunistic pullback to $135. Yield 2.95% (Analysts’ price target is $146.59)